atazanavir sulfate has been researched along with naloxone in 1 studies
| Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (naloxone) | Trials (naloxone) | Recent Studies (post-2010) (naloxone) |
|---|---|---|---|---|---|
| 1,102 | 246 | 590 | 20,134 | 1,257 | 3,321 |
| Protein | Taxonomy | atazanavir sulfate (IC50) | naloxone (IC50) |
|---|---|---|---|
| Cytochrome P450 2D6 | Homo sapiens (human) | 2 | |
| Delta-type opioid receptor | Mus musculus (house mouse) | 0.043 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0219 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.0019 | |
| Mu-type opioid receptor | Homo sapiens (human) | 0.0397 | |
| Delta-type opioid receptor | Homo sapiens (human) | 0.1896 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.05 | |
| Kappa-type opioid receptor | Homo sapiens (human) | 0.0795 | |
| Mu-type opioid receptor | Mus musculus (house mouse) | 0.0154 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.0089 | |
| Beta-2 adrenergic receptor | Cavia porcellus (domestic guinea pig) | 0.0055 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Altice, F; Botsko, M; Egan, JE; Fiellin, DA; Nandi, V; O'Connor, PG; Sullivan, LE; Tozzi, MJ; Vergara-Rodriguez, P | 1 |
1 other study(ies) available for atazanavir sulfate and naloxone
| Article | Year |
|---|---|
Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Chemical and Drug Induced Liver Injury; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; Humans; Naloxone; Oligopeptides; Opioid-Related Disorders; Pyridines | 2011 |